Preventing Hidden Nutrient Deficiencies GLP-1 therapy often leads to reduced food volume and variety, increasing the risk of deficiencies in: Protein Iron Calcium Vitamin D B vitamins Magnesium These deficiencies can show up as fatigue, hair loss, poor recovery, and even bone health issues
Balanced Perspective: Conditional Game Changer The evidence suggests that GLP-1 agonists represent a conditional game changertransformative for appropriate patients with adequate access and support, but with significant limitations that prevent universal application
While GLP-1RAs are guideline-recommended for CVD risk reduction in T2D, their impact on SAa potent CVD risk multiplierremains poorly understood
Similarly, expression of cell signature genes, transthyretin ( TTR ), vitamin Dbinding protein ( GC ), crystallin A2 ( CRYBA2 ), aldehyde dehydrogenase 1 family member A1 ( ALDH1A1 ), and transmembrane 4 L 6 family member 4 ( TM4SF4 ), was highest in the -3 and 4 subclusters (Figure 3D)
This high-touch, one-on-one support includes: GLP-1 Coverage Models with HealthCheck360 While GLP-1 coverage decisions ultimately rest with the employer and their benefits partners, the success of those decisions depends heavily on whats built around them
Although direct interactions are not expected based on FDA labeling, any medication change in patients on warfarin justifies increased vigilance